IP Library › Granted Patent US 11,129,823
Granted Patent B2
US 11,129,823 · App. 16/300,020 · Granted Sep 28, 2021

Combination treatment of ocular inflammatory disorders and diseases

Inventors: Todd Brady (Lexington, MA); Scott Young (E. Falmouth, MA)
Assignee: Aldeyra Therapeutics, Inc.
A61K31/47A61K9/0048A61K9/08A61K31/165A61K31/192A61K31/196A61K31/436A61K31/519A61K31/573A61K45/06A61K47/40A61P27/02A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,129,823
App. No.
16/300,020
Granted
Sep 28, 2021
Kind
B2
Abstract

The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.

Claims (6)

1. A method of treating non-infectious anterior uveitis, comprising administering to a subject with non-infectious anterior uveitis a therapeutically effective amount of Compound (2):

or a pharmaceutically acceptable salt thereof;

and prednisolone.

2. The method of claim 1 , wherein Compound (2) is formulated with a β-cyclodextrin or derivatives thereof.

3. The method of claim 2 , wherein the β-cyclodextrin or derivatives thereof is sulfobutylether-β-cyclodextrin or hydroxypropyl-β-cyclodextrin.

4. The method of claim 1 , wherein Compound (2) is administered topically at a concentration of about 0.1% w/v to about 5% w/v.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: BRADY, TODD; YOUNG, SCOTT
To: ALDEYRA THERAPEUTICS, INC.
Reel/Frame 048200/0214 →
Continuity (2)
Provisional Application 62333549 · May 9, 2016
Related Publication 20190183878A1 · Jun 20, 2019
Cited By (1)
US 12,240,816